Notable companies
The most notable companies in this group are Biogen (NASDAQ:BIIB), Intra-Cellular Therapies (NASDAQ:ITCI), Sarepta Therapeutics (NASDAQ:SRPT), Avadel Pharmaceuticals plc (NASDAQ:AVDL).
Industry description
The investment seeks to track the NYSE FactSet Global Neuro Biopharma and MedTech Index composed of U.S. and non-U.S. companies that could benefit from the growth and innovation in neuroscience.
The fund will invest at least 80% of its assets in the component securities of its index and in investments that have economic characteristics that are substantially identical to the component securities of its index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents as well as in securities not included in the index, but which BFA believes will help the fund track the index. It is non-diversified.
Market Cap
The average market capitalization across the iShares Neuroscience and Healthcare ETF ETF is 3.08B. The market cap for tickers in the group ranges from 10.54M to 35.69B. ARGX holds the highest valuation in this group at 35.69B. The lowest valued company is ATHA at 10.54M.
High and low price notable news
The average weekly price growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 1%. For the same ETF, the average monthly price growth was 18%, and the average quarterly price growth was 314%. NPCE experienced the highest price growth at 6%, while EWTX experienced the biggest fall at -30%.
Volume
The average weekly volume growth across all stocks in the iShares Neuroscience and Healthcare ETF ETF was 99%. For the same stocks of the ETF, the average monthly volume growth was 26% and the average quarterly volume growth was 124%
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Valuation Rating: 57
P/E Growth Rating: 80
Price Growth Rating: 72
SMR Rating: 86
Profit Risk Rating: 82
Seasonality Score: -14 (-100 ... +100)